MTOR and familial pancreatic carcinoma: Dual PI3K/mTOR inhibitors have gained significant interest given their ability to target both upstream and downstream in this signaling cascade, potentially inhibiting some feedback regulation of AKT.28 NVP-BEZ235 is a dual PI3K/mTOR inhibitor with an IC50 p110α of 4 nM, p110β of 75 nM and mTOR of 6 nM.29 To investigate the response of PIK3CA mutant pancreatic cancers secondary to PI3K pathway inhibition NVP-BEZ235 was administered to Pc1Pik3cap110* mice.